RESEARCH TRIANGLE PARK, N.C. – Margaret M. Mordin, MS, a health services strategist and researcher with over 15 yeas of experience, recently joined RTI Health Solutions (RTI-HS) as Senior Director of Outcomes Research and Regulatory Strategy.
Prior to RTI-HS, Ms. Mordin was a fourteen-year veteran of Covance Market Access Services. During her tenure there, Ms. Mordin held a number of positions of increasing responsibility. Most recently and for 7 years, she was Vice President in the Consulting Services Group where she was responsible for directing project teams in providing strategic consulting related to patient-reported and health economic outcomes in clinical development programs. In particular, she specialized in designing and implementing outcomes assessments for post-marketing studies and prospective trials intended for regulatory submission. Her research and consulting expertise includes patient-based outcomes in clinical programs, health-related quality-of-life and satisfaction surveys, outcomes analysis and publications, outcomes-related regulatory submission strategies, and health economic evaluations.
Earlier in her career, Ms. Mordin worked for New England Medical Center where she developed health outcomes assessments for both outpatient and inpatient clinical sites including orthopedics, cardiology, cardiothoracic surgery and nursing.
"I am delighted Margaret has joined our team," said Kati Copley-Merriman, MS, MBA, Global Head of Outcomes Research and Regulatory Strategy. "She brings broad health economics and outcomes research experience. In particular, her expertise in Phase IV studies, observational studies and diagnostic and medical devices will complement the existing expertise within RTI-HS."
Ms. Mordin earned her BA in Political Science and MS in Public Policy Analysis from the University of Rochester. She regularly presents at industry-related and therapeutically-aligned conferences and has numerous publications in peer-reviewed journals including Journal of Managed Care Pharmacy, American Journal of Clinical Dermatology, Clinical Cardiology, Quality of Life Research, Transplantation, Oncology, and New England Journal of Medicine. Ms. Mordin’s therapeutic expertise is extensive and includes age-related macular degeneration, asthma, cardiology, chronic pain, diabetes, Gaucher disease, HIV/AIDS, kidney transplantation, oncology, ophthalmology, Parkinson’s disease, psoriasis, orthopedics, and schizophrenia. In addition, Ms. Mordin has conducted outcomes research for multiple medical devices including: drug/device combination products, transdermal delivery systems, blood glucose monitoring systems, intravenous patient-controlled analgesia, multiple medication inhalation devices, photodynamic therapy, and digital mammography.
"I am excited to join such a distinguished group of consultants and scientists," said Ms. Mordin. "RTI-HS is committed to producing high quality work products for its clients—a commitment that is substantiated by the level of scientific rigor it applies to all its research. More than ever, this commitment to exceptional quality is necessary to thoroughly and effectively address the pressing regulatory, commercialization, and development issues that pharmaceutical companies face today."
About RTI Health Solutions
RTI Health Solutions provides scientifically rigorous research and consulting service in health economics, health outcomes, psychometrics, pricing and reimbursement, health preference assessment, epidemiology, pharmacovigilance, clinical development, and biostatistics to help biopharmaceutical companies successfully develop and gain market approval for their products.